Inpharma 1269 - 6 Jan 2001

■ The nitric oxide synthase inhibitor L-NAME* showssynergistic antitumour activity with melphalan andtumour necrosis factor (TNF)-α against soft tissuesarcoma in a rat hind limb after administration byisolated limb perfusion (ILP), report researchers fromThe Netherlands. They found that while no partial orcomplete responses were obtained in rats whichreceived ILP with L-NAME, TNF-α or melphalan alone,the addition of L-NAME to TNF-α and to melphalanproduced response rates of 64 and 63%, respectively.In addition, the response rate of 70% achieved byadministration of TNF-α plus melphalan was increasedto 100% by the addition of L-NAME. The researchersnote that adding L-NAME also prolonged the durationof response.* Nω-nitro-L-arginine-methyl ester

de Wilt JHW, et al. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-basedisolated limb perfusions. British Journal of Cancer 83: 1176-1182, No. 9, Nov2000 800851947

1

Inpharma 6 Jan 2001 No. 12691173-8324/10/1269-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved